Crushed by a trial failure, Tokai hands the reins — and the stock listing — to Otic
Last August, Tokai became the latest in a long string of public biotechs to hit a brick wall running at full speed. The late-stage failure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
